Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1992 Jul 15;285(Pt 2):481–488. doi: 10.1042/bj2850481

Additional biochemical findings in a patient and fetal sibling with a genetic defect in the sphingolipid activator protein (SAP) precursor, prosaposin. Evidence for a deficiency in SAP-1 and for a normal lysosomal neuraminidase.

B C Paton 1, B Schmid 1, B Kustermann-Kuhn 1, A Poulos 1, K Harzer 1
PMCID: PMC1132813  PMID: 1637339

Abstract

It has been shown that sphingolipid activator proteins (SAPs) 1 and 2 are encoded on the same gene along with two other putative activator proteins [Fürst, Machleidt & Sandhoff (1988) Biol. Chem. Hoppe-Seyler 369, 317-328 and O'Brien, Kretz, Dewji, Wenger, Esch & Fluharty (1988) Science 241, 1098-1101]. We have undertaken further biochemical investigations on a patient and fetal sibling, who were previously shown to have a unique sphingolipid storage disorder associated with an SAP-2 deficiency [Harzer, Paton, Poulos, Kustermann-Kuhn, Roggendorf, Grisar & Popp (1989) Eur. J. Pediatr. 149, 31-39]. The severity of their disorder suggested that other products of the SAP precursor or prosaposin gene may also be deficient. The turnover of cerebroside sulphate and globotriaosylceramide were investigated and were both impaired in fibroblasts from the patient and fetus. However, the activities of cerebroside sulphate sulphatase and globotriaosylceramide alpha-galactosidase in vitro were normal in cells from the fetus and patient respectively. In addition, there was an increase in cerebroside sulphate concentration in the kidney of the affected fetus. These results indicate that, in addition to the SAP-2 deficiency, there was a defect in SAP-1 function in this disorder. Additional increases in the concentration of monohexosyl- and dihexosyl-ceramide in the fetal kidney probably reflect the deficiency of SAP-2 in the case of monohexosylceramides, and the combined activator deficiency in the case of dihexosylceramides. Lactosylceramide-loading studies confirmed that there was a defect in the turnover of this lipid in fibroblasts from the affected patient and fetus but not from a patient with an isolated SAP-1 deficiency, or from patients with Krabbe disease, GM1 gangliosidosis or galactosialidosis. It has been suggested [Potier, Lamontagne, Michaud & Tranchemontagne (1990) Biochem. Biophys. Res. Commun. 173, 449-456] that the prosaposin gene also codes for lysosomal neuroaminidase. However, we found normal neuraminidase activity in fibroblasts from our patient, using assay conditions which are diagnostic for sialidosis patients. The role of prosaposin gene products in sphingolipid metabolism is discussed in view of our biochemical findings in this genetic disorder.

Full text

PDF
481

Images in this article

485Fig. 1.
on p.485

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berent B. L., Radin N. S. beta-Glucosidase activator protein from bovine spleen ("coglucosidase"). Arch Biochem Biophys. 1981 Apr 15;208(1):248–260. doi: 10.1016/0003-9861(81)90147-8. [DOI] [PubMed] [Google Scholar]
  2. Berent S. L., Radin N. S. Mechanism of activation of glucocerebrosidase by co-beta-glucosidase (glucosidase activator protein). Biochim Biophys Acta. 1981 Jun 23;664(3):572–582. doi: 10.1016/0005-2760(81)90134-x. [DOI] [PubMed] [Google Scholar]
  3. Christomanou H., Aignesberger A., Linke R. P. Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant. Biol Chem Hoppe Seyler. 1986 Sep;367(9):879–890. doi: 10.1515/bchm3.1986.367.2.879. [DOI] [PubMed] [Google Scholar]
  4. Christomanou H., Chabás A., Pámpols T., Guardiola A. Activator protein deficient Gaucher's disease. A second patient with the newly identified lipid storage disorder. Klin Wochenschr. 1989 Oct 2;67(19):999–1003. doi: 10.1007/BF01716064. [DOI] [PubMed] [Google Scholar]
  5. Christomanou H., Kleinschmidt T. Isolation of two forms of an activator protein for the enzymic sphingomyelin degradation from human Gaucher spleen. Biol Chem Hoppe Seyler. 1985 Mar;366(3):245–256. doi: 10.1515/bchm3.1985.366.1.245. [DOI] [PubMed] [Google Scholar]
  6. Collard M. W., Sylvester S. R., Tsuruta J. K., Griswold M. D. Biosynthesis and molecular cloning of sulfated glycoprotein 1 secreted by rat Sertoli cells: sequence similarity with the 70-kilodalton precursor to sulfatide/GM1 activator. Biochemistry. 1988 Jun 14;27(12):4557–4564. doi: 10.1021/bi00412a050. [DOI] [PubMed] [Google Scholar]
  7. Conzelmann E., Burg J., Stephan G., Sandhoff K. Complexing of glycolipids and their transfer between membranes by the activator protein for degradation of lysosomal ganglioside GM2. Eur J Biochem. 1982 Apr 1;123(2):455–464. doi: 10.1111/j.1432-1033.1982.tb19789.x. [DOI] [PubMed] [Google Scholar]
  8. Conzelmann E., Sandhoff K. AB variant of infantile GM2 gangliosidosis: deficiency of a factor necessary for stimulation of hexosaminidase A-catalyzed degradation of ganglioside GM2 and glycolipid GA2. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3979–3983. doi: 10.1073/pnas.75.8.3979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Conzelmann E., Sandhoff K. Purification and characterization of an activator protein for the degradation of glycolipids GM2 and GA2 by hexosaminidase A. Hoppe Seylers Z Physiol Chem. 1979 Dec;360(12):1837–1849. doi: 10.1515/bchm2.1979.360.2.1837. [DOI] [PubMed] [Google Scholar]
  10. Fabbro D., Grabowski G. A. Human acid beta-glucosidase. Use of inhibitory and activating monoclonal antibodies to investigate the enzyme's catalytic mechanism and saposin A and C binding sites. J Biol Chem. 1991 Aug 15;266(23):15021–15027. [PubMed] [Google Scholar]
  11. Fischer G., Jatzkewitz H. The activator of cerebroside-sulphatase. A model of the activation. Biochim Biophys Acta. 1978 Jan 27;528(1):69–76. doi: 10.1016/0005-2760(78)90053-x. [DOI] [PubMed] [Google Scholar]
  12. Fujibayashi S., Wenger D. A. Biosynthesis of the sulfatide/GM1 activator protein (SAP-1) in control and mutant cultured skin fibroblasts. Biochim Biophys Acta. 1986 Feb 28;875(3):554–562. doi: 10.1016/0005-2760(86)90077-9. [DOI] [PubMed] [Google Scholar]
  13. Fujibayashi S., Wenger D. A. Synthesis and processing of sphingolipid activator protein-2 (SAP-2) in cultured human fibroblasts. J Biol Chem. 1986 Nov 15;261(32):15339–15343. [PubMed] [Google Scholar]
  14. Fürst W., Machleidt W., Sandhoff K. The precursor of sulfatide activator protein is processed to three different proteins. Biol Chem Hoppe Seyler. 1988 May;369(5):317–328. doi: 10.1515/bchm3.1988.369.1.317. [DOI] [PubMed] [Google Scholar]
  15. Fürst W., Schubert J., Machleidt W., Meyer H. E., Sandhoff K. The complete amino-acid sequences of human ganglioside GM2 activator protein and cerebroside sulfate activator protein. Eur J Biochem. 1990 Sep 24;192(3):709–714. doi: 10.1111/j.1432-1033.1990.tb19280.x. [DOI] [PubMed] [Google Scholar]
  16. Hahn A. F., Gordon B. A., Hinton G. G., Gilbert J. J. A variant form of metachromatic leukodystrophy without arylsulfatase deficiency. Ann Neurol. 1982 Jul;12(1):33–36. doi: 10.1002/ana.410120106. [DOI] [PubMed] [Google Scholar]
  17. Handa S., Ariga T., Miyatake T., Yamakawa T. Presence of alpha-anomeric glycosidic configuration in the glycolipids accumulated in kidney with Fabry's disease. J Biochem. 1971 Mar;69(3):625–627. [PubMed] [Google Scholar]
  18. Harzer K., Paton B. C., Poulos A., Kustermann-Kuhn B., Roggendorf W., Grisar T., Popp M. Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses. Eur J Pediatr. 1989 Oct;149(1):31–39. doi: 10.1007/BF02024331. [DOI] [PubMed] [Google Scholar]
  19. Hineno T., Sano A., Kondoh K., Ueno S., Kakimoto Y., Yoshida K. Secretion of sphingolipid hydrolase activator precursor, prosaposin. Biochem Biophys Res Commun. 1991 Apr 30;176(2):668–674. doi: 10.1016/s0006-291x(05)80236-0. [DOI] [PubMed] [Google Scholar]
  20. Hiraiwa M., Uda Y., Nishizawa M., Miyatake T. Human placental sialidase: partial purification and characterization. J Biochem. 1987 May;101(5):1273–1279. doi: 10.1093/oxfordjournals.jbchem.a121991. [DOI] [PubMed] [Google Scholar]
  21. Hiraiwa M., Uda Y., Tsuji S., Miyatake T., Martin B. M., Tayama M., O'Brien J. S., Kishimoto Y. Human placental sialidase complex: characterization of the 60 kDa protein that cross-reacts with anti-saposin antibodies. Biochem Biophys Res Commun. 1991 Jun 28;177(3):1211–1216. doi: 10.1016/0006-291x(91)90670-3. [DOI] [PubMed] [Google Scholar]
  22. Ho M. W., O'Brien J. S. Gaucher's disease: deficiency of 'acid' -glucosidase and reconstitution of enzyme activity in vitro. Proc Natl Acad Sci U S A. 1971 Nov;68(11):2810–2813. doi: 10.1073/pnas.68.11.2810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ho M. W. Specificity of low molecular weight glycoprotein effector of lipid glycosidase. FEBS Lett. 1975 May 1;53(2):243–247. doi: 10.1016/0014-5793(75)80029-9. [DOI] [PubMed] [Google Scholar]
  24. Holtschmidt H., Sandhoff K., Fürst W., Kwon H. Y., Schnabel D., Suzuki K. The organization of the gene for the human cerebroside sulfate activator protein. FEBS Lett. 1991 Mar 25;280(2):267–270. doi: 10.1016/0014-5793(91)80308-p. [DOI] [PubMed] [Google Scholar]
  25. Holtschmidt H., Sandhoff K., Kwon H. Y., Harzer K., Nakano T., Suzuki K. Sulfatide activator protein. Alternative splicing that generates three mRNAs and a newly found mutation responsible for a clinical disease. J Biol Chem. 1991 Apr 25;266(12):7556–7560. [PubMed] [Google Scholar]
  26. Ida H., Kusano K., Suzuki H., Tokoro T., Eto Y. Galactosylceramide and galactosylsphingosine loading studies in cultured skin fibroblasts in human and murine globoid cell leukodystrophy. Biochem Biophys Res Commun. 1990 Jan 30;166(2):1053–1060. doi: 10.1016/0006-291x(90)90917-c. [DOI] [PubMed] [Google Scholar]
  27. Kobayashi T., Shinnoh N., Goto I., Kuroiwa Y. Hydrolysis of galactosylceramide is catalyzed by two genetically distinct acid beta-galactosidases. J Biol Chem. 1985 Dec 5;260(28):14982–14987. [PubMed] [Google Scholar]
  28. Kobayashi T., Shinnoh N., Goto I., Kuroiwa Y., Okawauchi M., Sugihara G., Tanaka M. Galactosylceramide- and lactosylceramide-loading studies in cultured fibroblasts from normal individuals and patients with globoid cell leukodystrophy (Krabbe's disease) and GM1-gangliosidosis. Biochim Biophys Acta. 1985 Jul 31;835(3):456–464. [PubMed] [Google Scholar]
  29. Kudoh T., Wenger D. A. Diagnosis of metachromatic leukodystrophy, Krabbe disease, and Farber disease after uptake of fatty acid-labeled cerebroside sulfate into cultured skin fibroblasts. J Clin Invest. 1982 Jul;70(1):89–97. doi: 10.1172/JCI110607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  31. Li S. C., Kihara H., Serizawa S., Li Y. T., Fluharty A. L., Mayes J. S., Shapiro L. J. Activator protein required for the enzymatic hydrolysis of cerebroside sulfate. Deficiency in urine of patients affected with cerebroside sulfatase activator deficiency and identity with activators for the enzymatic hydrolysis of GM1 ganglioside and globotriaosylceramide. J Biol Chem. 1985 Feb 10;260(3):1867–1871. [PubMed] [Google Scholar]
  32. Li S. C., Sonnino S., Tettamanti G., Li Y. T. Characterization of a nonspecific activator protein for the enzymatic hydrolysis of glycolipids. J Biol Chem. 1988 May 15;263(14):6588–6591. [PubMed] [Google Scholar]
  33. Lieser M., Harms E., Kern H., Bach G., Cantz M. Ganglioside GM3 sialidase activity in fibroblasts of normal individuals and of patients with sialidosis and mucolipidosis IV. Subcellular distribution and and some properties. Biochem J. 1989 May 15;260(1):69–74. doi: 10.1042/bj2600069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Mancini G. M., Hoogeveen A. T., Galjaard H., Mansson J. E., Svennerholm L. Ganglioside GM1 metabolism in living human fibroblasts with beta-galactosidase deficiency. Hum Genet. 1986 May;73(1):35–38. doi: 10.1007/BF00292661. [DOI] [PubMed] [Google Scholar]
  35. Mehl E., Jatzkewitz H. Eine Cerebrosidsulfatase aus Schweineniere. Hoppe Seylers Z Physiol Chem. 1964;339(1):260–276. [PubMed] [Google Scholar]
  36. Morimoto S., Martin B. M., Kishimoto Y., O'Brien J. S. Saposin D: a sphingomyelinase activator. Biochem Biophys Res Commun. 1988 Oct 14;156(1):403–410. doi: 10.1016/s0006-291x(88)80855-6. [DOI] [PubMed] [Google Scholar]
  37. Morimoto S., Martin B. M., Yamamoto Y., Kretz K. A., O'Brien J. S., Kishimoto Y. Saposin A: second cerebrosidase activator protein. Proc Natl Acad Sci U S A. 1989 May;86(9):3389–3393. doi: 10.1073/pnas.86.9.3389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Nakano T., Sandhoff K., Stümper J., Christomanou H., Suzuki K. Structure of full-length cDNA coding for sulfatide activator, a Co-beta-glucosidase and two other homologous proteins: two alternate forms of the sulfatide activator. J Biochem. 1989 Feb;105(2):152–154. doi: 10.1093/oxfordjournals.jbchem.a122629. [DOI] [PubMed] [Google Scholar]
  39. O'Brien J. S., Kishimoto Y. Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J. 1991 Mar 1;5(3):301–308. doi: 10.1096/fasebj.5.3.2001789. [DOI] [PubMed] [Google Scholar]
  40. O'Brien J. S., Kretz K. A., Dewji N., Wenger D. A., Esch F., Fluharty A. L. Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus. Science. 1988 Aug 26;241(4869):1098–1101. doi: 10.1126/science.2842863. [DOI] [PubMed] [Google Scholar]
  41. Paton B. C., Hughes J. L., Harzer K., Poulos A. Immunocytochemical localization of sphingolipid activator protein 2 (SAP-2) in normal and SAP-deficient fibroblasts. Eur J Cell Biol. 1990 Feb;51(1):157–164. [PubMed] [Google Scholar]
  42. Paton B. C., Poulos A. Analysis of the multiple forms of Gaucher spleen sphingolipid activator protein 2. Biochem J. 1988 Aug 15;254(1):77–84. doi: 10.1042/bj2540077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Potier M., Lamontagne S., Michaud L., Tranchemontagne J. Human neuraminidase is a 60 kDa-processing product of prosaposin. Biochem Biophys Res Commun. 1990 Nov 30;173(1):449–456. doi: 10.1016/s0006-291x(05)81079-4. [DOI] [PubMed] [Google Scholar]
  44. Poulos A., Ranieri E., Shankaran P., Callahan J. W. Studies on the activation of the enzymatic hydrolysis of sphingomyelin liposomes. Biochim Biophys Acta. 1984 Apr 18;793(2):141–148. doi: 10.1016/0005-2760(84)90315-1. [DOI] [PubMed] [Google Scholar]
  45. Prence E., Chakravorti S., Basu A., Clark L. S., Glew R. H., Chambers J. A. Further studies on the activation of glucocerebrosidase by a heat-stable factor from Gaucher spleen. Arch Biochem Biophys. 1985 Jan;236(1):98–109. doi: 10.1016/0003-9861(85)90609-5. [DOI] [PubMed] [Google Scholar]
  46. Sano A., Hineno T., Mizuno T., Kondoh K., Ueno S., Kakimoto Y., Inui K. Sphingolipid hydrolase activator proteins and their precursors. Biochem Biophys Res Commun. 1989 Dec 29;165(3):1191–1197. doi: 10.1016/0006-291x(89)92728-9. [DOI] [PubMed] [Google Scholar]
  47. Schlote W., Harzer K., Christomanou H., Paton B. C., Kustermann-Kuhn B., Schmid B., Seeger J., Beudt U., Schuster I., Langenbeck U. Sphingolipid activator protein 1 deficiency in metachromatic leucodystrophy with normal arylsulphatase A activity. A clinical, morphological, biochemical, and immunological study. Eur J Pediatr. 1991 Jun;150(8):584–591. doi: 10.1007/BF02072213. [DOI] [PubMed] [Google Scholar]
  48. Schnabel D., Schröder M., Fürst W., Klein A., Hurwitz R., Zenk T., Weber J., Harzer K., Paton B. C., Poulos A. Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene. J Biol Chem. 1992 Feb 15;267(5):3312–3315. [PubMed] [Google Scholar]
  49. Schnabel D., Schröder M., Sandhoff K. Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease. FEBS Lett. 1991 Jun 17;284(1):57–59. doi: 10.1016/0014-5793(91)80760-z. [DOI] [PubMed] [Google Scholar]
  50. Schröder M., Klima H., Nakano T., Kwon H., Quintern L. E., Gärtner S., Suzuki K., Sandhoff K. Isolation of a cDNA encoding the human GM2 activator protein. FEBS Lett. 1989 Jul 17;251(1-2):197–200. doi: 10.1016/0014-5793(89)81454-1. [DOI] [PubMed] [Google Scholar]
  51. Shapiro L. J., Aleck K. A., Kaback M. M., Itabashi H., Desnick R. J., Brand N., Stevens R. L., Fluharty A. L., Kihara H. Metachromatic leukodystrophy without arylsulfatase A deficiency. Pediatr Res. 1979 Oct;13(10):1179–1181. doi: 10.1203/00006450-197910000-00021. [DOI] [PubMed] [Google Scholar]
  52. Stevens R. L., Fluharty A. L., Kihara H., Kaback M. M., Shapiro L. J., Marsh B., Sandhoff K., Fischer G. Cerebroside sulfatase activator deficiency induced metachromatic leukodystrophy. Am J Hum Genet. 1981 Nov;33(6):900–906. [PMC free article] [PubMed] [Google Scholar]
  53. Tamaru T., Fujibayashi S., Brown W. R., Wenger D. A. Immunocytochemical localization of sphingolipid activator protein-1, the sulfatide/GM1 ganglioside activator, to lysosomes in human liver and colon. Histochemistry. 1986;86(2):195–200. doi: 10.1007/BF00493387. [DOI] [PubMed] [Google Scholar]
  54. Tanaka H., Suzuki K. Globoid cell leukodystrophy (Krabbe's disease). Metabolic studies with cultured fibroblasts. J Neurol Sci. 1978 Oct;38(3):409–419. doi: 10.1016/0022-510x(78)90146-6. [DOI] [PubMed] [Google Scholar]
  55. Trinchera M., Ghidoni R., Sonnino S., Tettamanti G. Recycling of glucosylceramide and sphingosine for the biosynthesis of gangliosides and sphingomyelin in rat liver. Biochem J. 1990 Sep 15;270(3):815–820. doi: 10.1042/bj2700815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Vogel A., Fürst W., Abo-Hashish M. A., Lee-Vaupel M., Conzelmann E., Sandhoff K. Identity of the activator proteins for the enzymatic hydrolysis of sulfatide, ganglioside GM1, and globotriaosylceramide. Arch Biochem Biophys. 1987 Dec;259(2):627–638. doi: 10.1016/0003-9861(87)90529-7. [DOI] [PubMed] [Google Scholar]
  57. Vogel A., Schwarzmann G., Sandhoff K. Glycosphingolipid specificity of the human sulfatide activator protein. Eur J Biochem. 1991 Sep 1;200(2):591–597. doi: 10.1111/j.1432-1033.1991.tb16222.x. [DOI] [PubMed] [Google Scholar]
  58. Wenger D. A., DeGala G., Williams C., Taylor H. A., Stevenson R. E., Pruitt J. R., Miller J., Garen P. D., Balentine J. D. Clinical, pathological, and biochemical studies on an infantile case of sulfatide/GM1 activator protein deficiency. Am J Med Genet. 1989 Jun;33(2):255–265. doi: 10.1002/ajmg.1320330223. [DOI] [PubMed] [Google Scholar]
  59. Wenger D. A., Sattler M., Roth S. A protein activator of galactosylceramide beta-galactosidase. Biochim Biophys Acta. 1982 Sep 14;712(3):639–649. doi: 10.1016/0005-2760(82)90293-4. [DOI] [PubMed] [Google Scholar]
  60. Zeigler M., Sury V., Bach G. The identification of lysosomal ganglioside sialidase in human cells. Eur J Biochem. 1989 Aug 1;183(2):455–458. doi: 10.1111/j.1432-1033.1989.tb14949.x. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES